ImmunoBiochem immunobiochem.com


Public lists: Cancer Therapeutics (1137)

ImmunoBiochem has created a technology that enables the development of antibody drug conjugates (ADCs) targeted at intracellular tumor antigens. ADCs comprise a class of potentiated biological therapeutics. ADCs combine the targeting capabilities of monocional antibodies with cytotoxic properties of small molecule cancer drugs to selectively and specifically destroy cancer cells while minimizing damage to normal tissues.

ImmunoBiochem has created a technology that enables the development of antibody drug conjugates (ADCs) targeted at intracellular tumor antigens. ADCs comprise a class of potentiated biological therapeutics. ADCs combine the targeting capabilities of ...Show all

Company (Alive / Active)

Phone: 416-897-2789

Fax:

1055 Bay Street
Suite 2007
Toronto, M5S 3A3
Ontario, Canada

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
ImmunoBiochem $0M Dec 11, 2017

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related ImmunoBiochem Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Undisclosed Angel InvestorsAngel Investor (Individual)Angel
JLabsIncubator/AcceleratorSan Diego, California, United StatesIncubator/Accelerator
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens Mar 18, 2016 Application